Treatment of severe osteoporosis:
at high risk of fracture, for whom treatment with other medicinal products approved for the treatment of osteoporosis is not possible due to, for example, contraindications or intolerance. In postmenopausal women, strontium ranelate reduces the risk of vertebral and hip fractures.
The decision to prescribe strontium ranelate should be based on an assessment of the individual patient’s overall risks.
For this indication, competent medicine agencies globally authorize below treatments:
For: Adults (18-64) Elders (65+)
Oral, 2 grams, once daily 120 minutes after dinner.
The recommended dose is 2 g once daily by oral administration.
Due to the nature of the treated disease, strontium ranelate is intended for long-term use.
The absorption of strontium ranelate is reduced by food, milk and derivative products and therefore, strontium ranelate should be administered in-between meals. Given the slow absorption, strontium ranelate should be taken at bedtime, preferably at least two hours after eating.
Patients treated with strontium ranelate should receive vitamin D and calcium supplements if dietary intake is inadequate.
Strontium ranelate should be taken at bedtime, preferably at least two hours after eating.
The granules in the sachets must be taken as a suspension in a glass containing a minimum of 30 ml (approximately one third of a standard glass) of water.